David Lebowitz
Stock Analyst at Citigroup
(3.96)
# 622
Out of 5,043 analysts
119
Total ratings
59.77%
Success rate
8.69%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $70.86 | +18.54% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $57.83 | +45.25% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $26.72 | +79.64% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $22.52 | -11.19% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $202.00 | +43.56% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $91.28 | +12.84% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $34.42 | +10.40% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $15.13 | +45.41% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $54.26 | +23.48% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $38.72 | +44.63% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $25.60 | -60.94% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.81 | -17.13% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $66.40 | -32.23% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $70.02 | -2.88% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $421.50 | -9.37% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $54.48 | +76.21% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.04 | +98.68% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $463.43 | -64.61% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $20.11 | +93.93% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.53 | +55.21% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.34 | +6,288.01% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.66 | +743.37% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $70.86
Upside: +18.54%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $57.83
Upside: +45.25%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $26.72
Upside: +79.64%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $22.52
Upside: -11.19%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $202.00
Upside: +43.56%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $91.28
Upside: +12.84%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $34.42
Upside: +10.40%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $15.13
Upside: +45.41%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $54.26
Upside: +23.48%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $38.72
Upside: +44.63%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $25.60
Upside: -60.94%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.81
Upside: -17.13%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $66.40
Upside: -32.23%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $70.02
Upside: -2.88%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $421.50
Upside: -9.37%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $54.48
Upside: +76.21%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.04
Upside: +98.68%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $463.43
Upside: -64.61%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $20.11
Upside: +93.93%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.53
Upside: +55.21%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.34
Upside: +6,288.01%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.66
Upside: +743.37%